An mTOR inhibiting drug similar to rapamycin (everolimus) plus a quinoline anti-malarial drug (hydroxychloroquine) might prevent recurrence of breast cancer.
See this previous post in the rapamycin group for a discussion of the mechanisms involved:
facebook.com/share/p/17xWTZj9n1
Quoted:
A recent Penn study from Angela DeMichele, MD, and Lewis Chodosh, MD, PhD, found that everolimus and hydroxychloroquine—two medicines already approved for other conditions—can dramatically reduce the dormant tumor cells that often cause cancer recurrence.
Penn Medicine's David Fajgenbaum, MD, a trailblazer in the field of drug repurposing, highlights how this breakthrough serves as a powerful reminder that some of the most promising cures might already be sitting on pharmacy shelves.
#rapamycinHD #mtorHD #hcqHD #chloroquineHD #everolimusHD #cancerHD #breastcancerHD



